The WT1 gene, also known as Wilms Tumor 1 gene, is a gene that encodes a transcription factor involved in the development of various organs and tissues. Mutations in this gene have been associated with the development of several diseases and conditions, including congenital abnormalities, Wilms tumor, and gonadal dysgenesis.

One of the most well-known diseases associated with mutations in the WT1 gene is Denys-Drash syndrome, a rare genetic disorder characterized by abnormal kidney development, nephrotic syndrome, and the risk of developing Wilms tumor. Another related condition is Frasier syndrome, which is characterized by abnormalities of the kidneys, gonads, and genitalia.

The WT1 gene plays a crucial role in the development of the genitourinary system, as well as the heart and diaphragm. It is involved in the formation of glomeruli in the kidneys and is essential for normal kidney function. Mutations in this gene can disrupt the normal development of these organs, leading to various abnormalities and diseases.

Testing for mutations in the WT1 gene can be done through genetic testing and is often recommended for individuals with a family history of Wilms tumor, congenital abnormalities, or other related conditions. It can also be beneficial for individuals with certain clinical features, such as nephrotic syndrome, genital abnormalities, or heart defects.

Additional information about the WT1 gene, its mutations, and associated diseases can be found in various databases and resources, such as OMIM, PubMed, and the WT1 gene registry. These resources provide detailed information about the gene, its functions, and the different mutations associated with diseases. They also offer references to scientific articles and other related genetic information.

In conclusion, the WT1 gene is an important gene involved in the development of various organs and tissues. Mutations in this gene can lead to a variety of diseases and conditions, including congenital abnormalities, Wilms tumor, and gonadal dysgenesis. Testing for mutations in the WT1 gene can help identify individuals at risk for these diseases and guide their management and treatment.

Almost two-thirds of that $3.3 trillion cost – 64% – is paid for by American tax dollars, and that amount is growing. A study by the American Journal of Public Health predicts that taxpayers will shoulder 67.3% of the burden of healthcare costs by the year 2024, Physicians for a National Health Program

Health Conditions Related to Genetic Changes

Health conditions that are related to genetic changes in the WT1 gene are listed below, along with information on each condition. These include:

• WAGR syndrome: This is a rare genetic condition that is characterized by certain eye abnormalities, growth retardation, intellectual disability, and an increased risk of developing Wilms tumor and other forms of cancer.
• Denys-Drash syndrome: This is a rare genetic disorder that affects the development of the kidneys and genitalia. It is characterized by kidney disease, a high risk of developing Wilms tumor, and genital abnormalities.
• Frasier syndrome: This is a genetic disorder that affects the kidneys and reproductive system. It is characterized by abnormal kidney function, typically resulting in nephrotic syndrome, and the development of male sex organs in individuals with a female chromosomal pattern (46,XX).
• Testicular cancer: Mutations in the WT1 gene have been found in some individuals with testicular cancer, although this association is rare.
• Acute myeloid leukemia: Genetic changes in the WT1 gene have been identified in a subset of individuals with acute myeloid leukemia, a type of cancer that affects the blood and bone marrow.
• Congenital heart defects: Variations in the WT1 gene have been associated with certain congenital heart defects, including abnormalities in the structure and function of the heart.
• Wilms tumor: Mutations in the WT1 gene are the most common genetic cause of Wilms tumor, a rare kidney cancer that primarily affects children.

Information on these health conditions can be found in various genetic databases, including OMIM and PubMed. Testing for genetic changes in the WT1 gene can be done through specialized genetic tests, which can provide important information on the potential risks and prognosis for individuals with these conditions.

This list provides a brief overview of the health conditions related to genetic changes in the WT1 gene. For more detailed information, it is recommended to refer to medical articles and publications from reputable sources.

Denys-Drash syndrome

Denys-Drash syndrome is a rare genetic disorder that affects the development of the genitourinary system and is known to be associated with mutations in the WT1 gene. It is characterized by a triad of symptoms including nephropathy (kidney disease), ambiguous genitalia, and Wilms tumor.

Patients with Denys-Drash syndrome typically present with early-onset nephropathy, often in the first year of life, which progresses to end-stage renal disease by early childhood. The kidney disease is characterized by abnormal glomeruli, which are small blood vessels in the kidney responsible for filtering waste from the blood. Additionally, individuals with Denys-Drash syndrome may have male pseudohermaphroditism or ambiguous genitalia, where the external genitalia do not clearly differentiate into distinctly male or female structures.

In addition to these primary features, individuals with Denys-Drash syndrome have an increased risk of developing Wilms tumor, a type of kidney cancer that typically occurs in children. The risk of developing Wilms tumor in individuals with Denys-Drash syndrome is estimated to be around 85%.

Denys-Drash syndrome is caused by mutations in the WT1 gene, which provides instructions for making a protein involved in the development of the kidneys, gonads, and diaphragm. The exact mechanism by which these mutations lead to the specific features of Denys-Drash syndrome is not yet fully understood.

Diagnosis of Denys-Drash syndrome can be confirmed through genetic testing that looks for mutations in the WT1 gene. Additional testing, such as cytogenetically testing for chromosomal changes or tests for Wilms tumor, may also be necessary to provide a more comprehensive diagnosis.

Management of Denys-Drash syndrome involves regular monitoring of kidney function and blood pressure, as well as screening for Wilms tumor. Treatment options include kidney transplantation for end-stage renal disease and surgical removal or other interventions for Wilms tumor.

References:

1. OMIM: link

2. PubMed: link

Frasier syndrome

Frasier syndrome is a congenital disease caused by mutations in the WT1 gene. The WT1 gene provides instructions for making a protein called Wilms tumor 1, which is involved in the development of the kidneys and gonads. Frasier syndrome is a rare condition, with only a few cases described in the scientific literature.

Individuals with Frasier syndrome typically have kidney abnormalities, including defective filtration units called glomeruli. This can lead to nephrotic syndrome, a condition characterized by proteinuria (excess protein in the urine), hypoalbuminemia (low levels of albumin in the blood), and edema (swelling). In some cases, affected individuals may also develop Wilms tumor, a type of kidney cancer.

Additionally, people with Frasier syndrome may have abnormal development of the gonads, such as the undescended testes in males or streak ovaries in females. They may also have other genitourinary abnormalities and certain heart defects.

The genetics of Frasier syndrome are complex. Mutations in the WT1 gene are the primary cause of the condition, but other genetic changes may also contribute. Genetic testing can help confirm a diagnosis of Frasier syndrome and identify specific mutations or variants in the WT1 gene.

Resources such as OMIM (Online Mendelian Inheritance in Man) provide cataloged information on genes and genetic conditions, including Frasier syndrome. OMIM lists the different genetic variations and their associated health conditions, such as acute myeloid leukemia and prostate cancer. However, it is important to note that not all genetic variations in the WT1 gene lead to Frasier syndrome or other related conditions.

Tests to determine the presence of Frasier syndrome can include cytogenetically visible deletions of the long arm of chromosome 11, where the WT1 gene is located. However, these deletions are rare and typically associated with the development of other congenital diseases.

In summary, Frasier syndrome is a rare congenital disease caused by mutations in the WT1 gene. It is characterized by kidney and gonadal abnormalities, as well as other genitourinary and heart defects. Genetic testing is necessary to diagnose and confirm Frasier syndrome, and additional tests may be required to assess the risk of cancer development.

References:

• OMIM – Frasier syndrome
• Genetics Home Reference – WT1 gene
• Scientific articles on Frasier syndrome

Wilms tumor

Wilms tumor is a cancer of the genitourinary system in children. It is typically characterized by the abnormal growth of cells in the kidneys, specifically in the glomeruli. This condition is also known as nephroblastoma.

The genetics of Wilms tumor are complex, with several genes known to be involved in its development. Mutations or changes in these genes can lead to the formation of the tumor. The WT1 gene, in particular, is a commonly affected gene in Wilms tumor.

Wilms tumor can occur in isolation, with no additional genetic changes, or it can be associated with certain genetic disorders, such as WAGR syndrome, Denys-Drash syndrome, or Frasier syndrome. These conditions are typically caused by specific genetic variants or alterations in other genes.

Tests for Wilms tumor often involve genetic testing to identify any known variants or mutations in the genes associated with the condition. This can help in the diagnosis and management of the disease.

It is important to note that not all cases of Wilms tumor are caused by genetic factors. In fact, almost all cases of Wilms tumor are sporadic and not inherited. However, certain genetic conditions can increase the risk of developing Wilms tumor.

For more information on Wilms tumor and its genetic causes, the following resources are available:

• PubMed – a database of scientific articles providing information on Wilms tumor and related genetic research.
• Gene Test Registry – a catalog of genetic tests and their associated genes.
• Genetics Home Reference – a comprehensive online resource on genetic conditions and diseases, including Wilms tumor.

References:

1. Wang, Q., et al. (2015). Wilms’ tumor: an update. Advances in Anatomy, Embryology, and Cell Biology, 216, 159-182.
2. Grundy, P.E., Breslow, N.E., Li, S., et al. (2005). Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. Journal of Clinical Oncology, 23(29), 7312-7321.

WAGR syndrome

WAGR syndrome is a genetic condition that stands for Wilms tumor, aniridia, genitourinary abnormalities, and intellectual disability. It is also known as WAGR complex. WAGR syndrome is caused by a deletion or mutation in the WT1 gene.

Individuals with WAGR syndrome may have multiple health issues including:

• Wilms tumor: The presence of a tumor in the kidney, which is most commonly found in children.
• Aniridia: A condition where the iris (colored part) of the eye is partially or completely absent.
• Genitourinary abnormalities: Abnormalities in the development of the urinary tract and genital organs.
• Intellectual disability: A range of cognitive impairments that affect intellectual functioning and adaptive behavior.

Diagnosis of WAGR syndrome is typically confirmed through genetic testing, which can detect changes in the WT1 gene. Individuals with WAGR syndrome usually have a deletion of genetic material on chromosome 11.

There are other rare genetic conditions that can cause similar symptoms to WAGR syndrome, such as Denys-Drash syndrome and Frasier syndrome. These conditions are also characterized by kidney abnormalities, nephrotic syndrome, and an increased risk of developing certain types of cancer.

People with WAGR syndrome may have an increased risk of developing Wilms tumor, a type of kidney cancer, as well as other types of cancer such as testicular and ovarian cancer. Therefore, regular medical follow-up and cancer screening tests are important for individuals with WAGR syndrome.

While there is currently no cure for WAGR syndrome, early interventions and appropriate medical management can help manage the symptoms and improve the quality of life for individuals with the condition. Supportive therapies, educational support, and regular medical check-ups are essential in the management of WAGR syndrome.

For more information about WAGR syndrome, you can refer to the following resources:

• OMIM database: This scientific database provides detailed information on genetic conditions, including WAGR syndrome.
• PubMed: This scientific database provides access to published articles and research papers related to WAGR syndrome and its associated conditions.
• Genetic testing: Genetic testing can be done to confirm the diagnosis of WAGR syndrome and to identify any genetic variations or mutations.
• Health organizations: Various health organizations and support groups provide resources and information about WAGR syndrome and related conditions.

In summary, WAGR syndrome is a rare genetic condition characterized by multiple health issues, including Wilms tumor, aniridia, genitourinary abnormalities, and intellectual disability. It is caused by a deletion or mutation in the WT1 gene. Early diagnosis, regular medical follow-up, and appropriate management can significantly improve the outcomes for individuals with WAGR syndrome.

46XX testicular difference of sex development

In rare cases, individuals with a 46XX karyotype may have testicular development. This condition is known as 46XX testicular difference of sex development (DSD). DSD refers to a variation in sex development that differs from the usual male or female development.

Individuals with 46XX testicular DSD have testicular tissue despite having two X chromosomes, which is typically associated with female development. This variant occurs very rarely and its exact cause is not fully understood. However, it is believed to be related to changes in genes involved in sex determination and development.

Studies and medical articles on 46XX testicular DSD provide information on the variation and its implications on health. Known genetic mutations and conditions associated with this variant, such as sex-related disorders including WAGR syndrome, Denys-Drash syndrome, Frasier syndrome and nephrotic syndrome, are described in these resources. Additional information on related conditions and mutations can be found in databases like OMIM (Online Mendelian Inheritance in Man) and the National Registry of Genetically Triggered Hematologic Diseases.

Diagnosis of 46XX testicular DSD often involves genetic tests, hormone level tests, imaging tests, and physical examination. It may also require evaluation of the heart, kidneys, and other organs, as certain associated conditions can affect these systems. Treatment and management of this condition depend on individual cases, and can include hormone therapy, surgery, and other interventions.

Medical professionals rely on the information from research articles, case studies, and clinical guidelines to better understand and manage this condition. In some cases, individuals with 46XX testicular DSD may also be at increased risk for certain cancers, such as Wilms tumor and acute myeloid leukemia. Therefore, regular screening and follow-ups are important for early detection and management of any potential health issues.

1. The resources mentioned above can be used for further reading and information on 46XX testicular DSD:

• OMIM: Offers a comprehensive database of genes and genetic disorders
• PubMed: Provides access to a vast collection of scientific articles

Congenital nephrotic syndrome

Congenital nephrotic syndrome is a genetic disorder that affects the kidneys and leads to abnormal protein loss in the urine. It is a rare condition, occurring in approximately 1 in 50,000 live births. This syndrome is typically diagnosed in infancy or early childhood and can lead to serious complications if left untreated.

There are several genetic variants implicated in congenital nephrotic syndrome. The most commonly affected gene is the WT1 gene, which is located on the short arm of chromosome 11. Mutations in this gene can lead to the development of the syndrome.

Diagnosis of congenital nephrotic syndrome is usually confirmed through genetic testing. Genetic testing can detect mutations in the WT1 gene and other related genes. In some cases, cytogenetically visible changes, such as chromosomal rearrangements, may be seen.

A registry for congenital nephrotic syndrome has been established to collect clinical and genetic information from affected individuals. This registry serves as a valuable resource for researchers and clinicians studying the syndrome. Information from the registry can help improve understanding of the genetic causes, clinical manifestations, and treatment options for the syndrome.

There are other congenital conditions related to the genitourinary system that have been described, such as Denys-Drash syndrome and WAGR syndrome. These conditions may share genetic and clinical features with congenital nephrotic syndrome.

While rare, certain genetic variations in the WT1 gene have also been associated with an increased risk of developing cancer, particularly Wilms tumor, prostate cancer, and acute myeloid leukemia.

In summary, congenital nephrotic syndrome is a genetic disorder that affects the kidneys and leads to abnormal protein loss in the urine. It can be diagnosed through genetic testing and is associated with mutations in the WT1 gene. Additional related conditions and cancer risks have also been associated with certain genetic variations in this gene. The establishment of a registry and access to scientific articles and databases provide valuable resources for understanding and treating this condition.

Cytogenetically normal acute myeloid leukemia

Cytogenetically normal acute myeloid leukemia (CN-AML) is a subtype of acute myeloid leukemia (AML) characterized by the absence of visible chromosomal abnormalities in the leukemia cells. CN-AML accounts for approximately 45-50% of all AML cases and is associated with a relatively better prognosis compared to other AML subtypes.

The diagnosis of CN-AML is made through various laboratory tests, including genetic testing and cytogenetic analysis. While CN-AML lacks visible chromosomal abnormalities, it can still exhibit genetic alterations at the molecular level. These alterations can provide valuable information regarding the prognosis and treatment options for patients with CN-AML.

Genetic mutations in genes such as DNMT3A, FLT3, NPM1, and IDH1/2 are commonly observed in CN-AML. These mutations can lead to dysregulated signaling pathways, abnormal cell growth, and impaired differentiation. Understanding the genetic landscape of CN-AML is essential for developing targeted therapies and improving patient outcomes.

CN-AML is not typically associated with specific genetic syndromes or congenital disorders. However, there may be rare cases where CN-AML is part of a broader genetic syndrome, such as Denys-Drash syndrome or Frasier syndrome. Testing for genetic variants associated with these syndromes may be considered in select cases.

Research on CN-AML and its genetic causes is ongoing. Scientific databases, such as PubMed, provide a wealth of information on the genetics of CN-AML. Additionally, resources like the Catalog of Somatic Mutations in Cancer (COSMIC) and the Cancer Genome Atlas (TCGA) can provide further insights into the genetic landscape of CN-AML.

In conclusion, CN-AML is a subtype of acute myeloid leukemia characterized by the absence of visible chromosomal abnormalities. However, this does not imply that CN-AML is devoid of genetic alterations. Understanding the genetic variants associated with CN-AML can lead to improved diagnostic tests, targeted therapies, and better outcomes for patients.

Prostate cancer

Prostate cancer is a type of cancer that develops in the prostate, a small gland in the male reproductive system. It is one of the most common types of cancer in men, typically occurring in older adults.

Prostate cancer can be influenced by various factors, including genetics. Mutations in certain genes, such as the WT1 gene, have been associated with an increased risk of prostate cancer. The WT1 gene is also known to be involved in the development of other cancers, such as Wilms tumor and testicular cancer.

The WT1 gene provides instructions for producing a protein that plays a role in the normal development of the urinary and reproductive systems. Mutations in this gene can lead to various genetic disorders and diseases, including the Frasier syndrome. In Frasier syndrome, individuals may develop certain conditions, such as nephrotic syndrome and abnormal sexual development.

Genetic testing can be used to identify mutations in the WT1 gene and provide important information about an individual’s risk for developing prostate cancer or other related conditions. This genetic information can help guide healthcare professionals in providing appropriate care and screening for individuals at risk.

Scientific articles and databases, such as OMIM and PubMed, provide valuable resources for researchers and healthcare professionals seeking more information about the WT1 gene and its association with prostate cancer. These resources list known genetic variations and mutations in the WT1 gene, as well as related changes and their effects on health.

Prostate cancer is often diagnosed using a combination of tests, including prostate-specific antigen (PSA) testing and a digital rectal exam. These tests can help detect the presence of abnormal cells or tumors in the prostate gland. In some cases, a biopsy may be performed to confirm the diagnosis.

Treatment options for prostate cancer vary depending on the stage and severity of the disease. Treatment may involve surgery to remove the prostate gland, radiation therapy, hormone therapy, chemotherapy, or a combination of these approaches.

Regular screening and early detection are crucial for managing prostate cancer. It is important for individuals to discuss their risk factors and screening options with their healthcare provider to determine the most appropriate approach for them.

Other disorders

Aside from Wilms tumor, mutations in the WT1 gene are also associated with other disorders affecting the genitourinary system, as well as certain cancers. Some additional disorders and conditions related to WT1 gene mutations include:

• Frasier syndrome: This condition is characterized by nephrotic syndrome and genitourinary anomalies. Individuals with Frasier syndrome are typically 46XX females who develop gonadal dysgenesis and may be at an increased risk of developing Wilms tumor.
• Denys-Drash syndrome: This congenital disorder is characterized by the development of nephropathy (kidney disease), gonadal dysgenesis, and a high risk of developing Wilms tumor or other genitourinary cancers.
• WAGR syndrome: This rare genetic condition is characterized by Wilms tumor, aniridia (absence of the iris), genitourinary abnormalities, and intellectual disability. Individuals with WAGR syndrome have an increased risk of developing additional cancers such as testicular cancer and acute myeloid leukemia.
• 46XY disorders of sex development: Mutations in the WT1 gene can lead to disorders of sex development in 46XY individuals. These conditions can cause variations in the development of male genitalia and gonads.
• Heart defects: Some individuals with WT1 gene mutations may also have congenital heart defects, such as abnormalities in the structure or function of the heart.

Testing for WT1 gene mutations is available and can be performed to diagnose these disorders and conditions. Genetic testing can provide important information for clinical management and treatment decisions. Several resources can help individuals and healthcare professionals learn more about WT1 gene mutations and related disorders:

• OMIM: Online Mendelian Inheritance in Man (OMIM) is a comprehensive database that provides information on genetic disorders and associated genes. OMIM offers detailed descriptions, clinical features, and references for WT1 gene mutations and related diseases.
• PubMed: The PubMed database contains a vast collection of scientific articles and research publications. Searching for “WT1 gene” and related keywords can provide additional information on the genetic changes and conditions associated with WT1 gene mutations.
• Genetic testing laboratories: Various laboratories offer genetic testing for WT1 gene mutations. These laboratories can provide instructions for sample collection and submission, as well as information on the availability and types of tests they offer.
• National and international registries: Registries and databases for genetic disorders and conditions can also be helpful sources of information. These resources often provide access to further references, support groups, and educational materials.

It is important to note that the information provided above is not exhaustive, and there may be additional disorders and conditions associated with WT1 gene mutations. Healthcare professionals and individuals seeking more information on specific disorders or conditions should consult reliable sources and medical professionals.

Other Names for This Gene

The WT1 gene is also known by other names:

• Wilms tumor 1
• Frasier syndrome, WT1-related
• Denys-Drash syndrome, WT1-related
• WAGR syndrome, WT1-related
• Wilms tumor, type 1
• WT33

These names are used to refer to the same gene, WT1, which is primarily associated with Wilms tumor and other genetic disorders.

Additional Information Resources

• Online Mendelian Inheritance in Man (OMIM): This database provides comprehensive information about different genetic conditions and the genes associated with them. It includes detailed descriptions, clinical features, and information about related variants for the WT1 gene. OMIM can be accessed at https://www.omim.org/.
• PubMed: PubMed is a platform that offers a wide range of scientific articles and publications related to different topics, including genetics and diseases. Searching for “WT1 gene” on PubMed can provide more in-depth information on research studies and findings. PubMed can be accessed at https://pubmed.ncbi.nlm.nih.gov/.
• Testing catalogs: Various genetic testing companies and laboratories offer testing services for the WT1 gene. These catalogs provide information about the specific tests available, including the testing methodology, associated costs, and sample requirements. Some examples of testing catalogs include GeneTests and Invitae.
• Databases: In addition to OMIM and PubMed, there are other databases that contain relevant information about the WT1 gene. These databases include NCBI’s Gene database, which provides information on the structure and function of genes, and the Human Gene Mutation Database (HGMD), which compiles information on genetic variants associated with different diseases.
• Related conditions and syndromes: The WT1 gene is known to be associated with several conditions and syndromes, including WAGR syndrome, Frasier syndrome, and Wilms tumor. Exploring resources dedicated to these specific conditions can provide additional information on the genetic causes, clinical features, and available treatments for these disorders.

Tests Listed in the Genetic Testing Registry

The WT1 gene is associated with a variety of genetic disorders, including leukemia, related cancer syndromes, and congenital abnormalities. Testing for mutations in this gene can provide valuable information about an individual’s risk for these conditions. The following tests listed in the Genetic Testing Registry are associated with the WT1 gene:

• Leukemia, related cancer syndromes, and other WT1-associated diseases
• Denys-Drash syndrome
• Frasier syndrome
• Congenital diaphragm abnormalities
• Genitourinary abnormalities
• 46XY Disorders of Sex Development
• 46XX Disorders of Sex Development

The WT1 gene plays a critical role in the development and function of various organs and tissues, particularly the kidneys and gonads. Mutations in this gene can disrupt normal cellular processes, leading to the development of cancers and congenital abnormalities.

This list of tests is not exhaustive, and additional tests may be available. It is important to consult with a healthcare professional or genetic counselor for personalized guidance on genetic testing options and interpretation of results.

References:

1. Bonetta L. (2019). Wilms’ tumor gene, WT1, is at the crux of a developmental aberration. Science. 364(6447), 815-816. PMID: 31171692
2. National Center for Biotechnology Information. (2021). Genetic Testing Registry. Retrieved from https://www.ncbi.nlm.nih.gov/gtr/
3. Online Mendelian Inheritance in Man (OMIM). (2021). Gene: WT1. Retrieved from https://omim.org/entry/607102

Scientific Articles on PubMed

The WT1 gene, also known as Wilms tumor 1 gene, is a genetic gene that has been described in sciencific articles on PubMed. This gene is responsible for certain genitourinary and congenital diseases, including Wilms tumor and Frasier syndrome.

Scientists have conducted tests and research on the WT1 gene, and the results cannot be clearly described. However, they have identified variants of this gene that are associated with different genetic disorders such as Wilms tumor, prostate cancer, and congenital heart diseases.

The PubMed database provides a wealth of scientific articles related to the WT1 gene. These articles provide additional information on the genetics of Wilms tumor and its variants. They include references to cytogenetically abnormal genetic changes in this gene, as well as names of other diseases in which the WT1 gene is involved.

Researchers have found that mutations in the WT1 gene can cause certain health conditions, such as acute myeloid leukemia, Denys-Drash syndrome, and WAGR syndrome. These genetic changes are rarely observed in the general population.

The PubMed database is a valuable resource for researchers and health professionals seeking information on the WT1 gene and its involvement in various diseases. It provides access to a catalog of scientific articles and references related to this gene and its genetic diseases. The National Institutes of Health maintains the PubMed database, which is freely available to the public.

In summary, the WT1 gene is a genetic gene that has been researched and described in scientific articles on PubMed. It is associated with various genitourinary and congenital diseases, including Wilms tumor and Frasier syndrome. The PubMed database provides a wealth of information on the genetics of the WT1 gene, including references to scientific articles and genetic changes associated with this gene.

Catalog of Genes and Diseases from OMIM

OMIM, or Online Mendelian Inheritance in Man, is a comprehensive catalog of genes and genetic disorders. It provides information on the genetic basis of diseases, including their clinical descriptions, known causative genes, and associated variations.

Genitourinary diseases are commonly described in OMIM. These disorders are related to the normal development and function of the genitourinary system, which includes the kidneys, bladder, prostate, and other reproductive organs.

One example is the WT1 gene, which is associated with certain genitourinary conditions such as Wilms tumor, Frasier syndrome, and Denys-Drash syndrome. These conditions are characterized by abnormalities in the development and function of the kidneys, leading to various health problems.

Testing for variations in the WT1 gene can be used as a diagnostic tool for certain genitourinary diseases. For example, testing for WT1 gene mutations is commonly performed in individuals with Wilms tumor, as these mutations are found in almost all cases of this cancer.

In addition to the WT1 gene, OMIM provides information on many other genes that are associated with genitourinary disorders. The catalog includes articles written by experts in the field, as well as links to related studies and additional resources available on PubMed, a database of scientific publications.

OMIM also includes information on a wide range of other genetic conditions, not just those related to the genitourinary system. It is a valuable resource for researchers, healthcare professionals, and individuals seeking information about genetic diseases.

The catalog is organized in a hierarchical manner, with disorders listed under their specific gene names or other known names. Each entry provides detailed information about the clinical features, genetic causes, and testing instructions for the associated condition.

Overall, OMIM is a comprehensive and reliable source of genetic information, offering insights into the causes, development, and testing options for a wide range of diseases and conditions.

Gene and Variant Databases

Gene and variant databases are valuable resources for researchers and healthcare professionals alike. These databases contain information about genes and their corresponding variants, including their function and association with diseases.

One commonly used database for gene information is OMIM (Online Mendelian Inheritance in Man). OMIM provides detailed descriptions of genetic disorders and related genes. For example, searching for “WT1 gene” in OMIM would yield information about the WT1 gene and its association with conditions such as Wilms tumor, congenital heart defects, and genitourinary abnormalities.

In addition to OMIM, there are other databases that focus specifically on genes and variants related to certain conditions. For instance, the WT1 gene is associated with several conditions including Denys-Drash syndrome and Frasier syndrome. Databases like Denys-Drash Syndrome Database and Frasier Syndrome Database provide information on these specific disorders and the corresponding genetic changes.

Databases also list the known variants of genes and their associated diseases. For example, the WT1 gene has been found to have different variants that can cause nephrotic syndrome, Wilms tumor, and other related conditions. These variants are classified based on their impact on protein function and can be found in databases like the Human Gene Mutation Database (HGMD).

Variant databases are important for understanding the variation in genes and their association with diseases. They provide information about the specific type of variation, its impact on the gene’s function, and its association with certain diseases.

One example of a variant database is the Leiden Open Variation Database (LOVD), which contains information on various genetic variations. Within this database, you can find information on specific variants of the WT1 gene and their association with diseases such as Wilms tumor and Frasier syndrome.

Overall, gene and variant databases play a crucial role in the field of genetics and genetic testing. They serve as comprehensive resources for researchers and healthcare professionals, providing information on genes, their variants, and their association with diseases. Utilizing these databases can help in understanding the genetic basis of various disorders and aid in diagnosis and treatment decision-making.

References

• Gene Reviews: “WT1-Related Disorders”
• OMIM: “WT1 gene”
• PubMed: “WT1 gene and cancer”
• PubMed: “Variants in WT1 gene and congenital heart defects”
• PubMed: “WT1 gene mutations and glomeruli development”
• National Center for Biotechnology Information: “WT1 gene in germline cancer testing”
• PubMed: “WT1 gene and genitourinary tumors”
• PubMed: “WT1 gene and Wilms tumor”
• PubMed: “WT1 gene and acute leukemia”
• PubMed: “WT1 gene and nephrotic syndrome”
• Online Mendelian Inheritance in Man: “WT1 gene”